Research ArticleClinical Studies
Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series
HIROSHI AOKI, NAOKI MATSUMOTO, HIROSHI TAKAHASHI, MASAYUKI HONDA, TOMOHIRO KANEKO, SHUHEI ARIMA, TOMOTAKA ISHII, TAKU MIZUTANI, RYOTA MASUZAKI, KAZUSHIGE NIREI, HIROAKI YAMAGAMI, MASAHIRO OGAWA, TATSUO KANDA, MITSUHIKO MORIYAMA and KATSUHIRO MIURA
Anticancer Research December 2021, 41 (12) 6225-6230; DOI: https://doi.org/10.21873/anticanres.15442
HIROSHI AOKI
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
NAOKI MATSUMOTO
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
HIROSHI TAKAHASHI
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
MASAYUKI HONDA
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
TOMOHIRO KANEKO
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
SHUHEI ARIMA
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
TOMOTAKA ISHII
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
TAKU MIZUTANI
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
RYOTA MASUZAKI
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
KAZUSHIGE NIREI
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
HIROAKI YAMAGAMI
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
MASAHIRO OGAWA
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
TATSUO KANDA
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
MITSUHIKO MORIYAMA
1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
KATSUHIRO MIURA
2Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
patientACCESS
patientACCESS - Patients desiring access to articles
In this issue
Anticancer Research
Vol. 41, Issue 12
December 2021
Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series
HIROSHI AOKI, NAOKI MATSUMOTO, HIROSHI TAKAHASHI, MASAYUKI HONDA, TOMOHIRO KANEKO, SHUHEI ARIMA, TOMOTAKA ISHII, TAKU MIZUTANI, RYOTA MASUZAKI, KAZUSHIGE NIREI, HIROAKI YAMAGAMI, MASAHIRO OGAWA, TATSUO KANDA, MITSUHIKO MORIYAMA, KATSUHIRO MIURA
Anticancer Research Dec 2021, 41 (12) 6225-6230; DOI: 10.21873/anticanres.15442
Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series
HIROSHI AOKI, NAOKI MATSUMOTO, HIROSHI TAKAHASHI, MASAYUKI HONDA, TOMOHIRO KANEKO, SHUHEI ARIMA, TOMOTAKA ISHII, TAKU MIZUTANI, RYOTA MASUZAKI, KAZUSHIGE NIREI, HIROAKI YAMAGAMI, MASAHIRO OGAWA, TATSUO KANDA, MITSUHIKO MORIYAMA, KATSUHIRO MIURA
Anticancer Research Dec 2021, 41 (12) 6225-6230; DOI: 10.21873/anticanres.15442
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.